These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26142634)

  • 1. Heart Failure Prevention and Team-based Interventions.
    Heidenreich P
    Heart Fail Clin; 2015 Jul; 11(3):349-58. PubMed ID: 26142634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment and risk in heart failure: gaps in evidence or quality?
    Peterson PN; Rumsfeld JS; Liang L; Hernandez AF; Peterson ED; Fonarow GC; Masoudi FA;
    Circ Cardiovasc Qual Outcomes; 2010 May; 3(3):309-15. PubMed ID: 20388872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Modern therapy of cardiac insufficiency].
    Stojsić D; Jelkić N
    Med Pregl; 1999; 52(3-5):113-24. PubMed ID: 10518395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of heart failure: effective strategies to combat the growing epidemic.
    Fonarow GC; Horwich TB
    Rev Cardiovasc Med; 2003; 4(1):8-17. PubMed ID: 12684599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Kubota T; Takeshita A
    Nihon Rinsho; 2003 May; 61(5):801-6. PubMed ID: 12755006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preventive care in heart failure].
    Cserhalmi L
    Orv Hetil; 2003 Dec; 144(52):2553-9. PubMed ID: 15005064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure.
    Tsuchihashi-Makaya M; Furumoto T; Kinugawa S; Hamaguchi S; Goto K; Goto D; Yamada S; Yokoshiki H; Takeshita A; Tsutsui H;
    Hypertens Res; 2010 Mar; 33(3):197-202. PubMed ID: 19960016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Team-based Care for Advanced Heart Failure.
    Wever-Pinzon O; Drakos SG; Fang JC
    Heart Fail Clin; 2015 Jul; 11(3):467-77. PubMed ID: 26142642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role of ACE inhibitors and angiotensin receptor blockers in the treatment and prevention of chronic heart failure].
    Kárpáti P
    Orv Hetil; 2005 May; 146(18):827-31. PubMed ID: 15926627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart failure: recent advances in prevention and treatment.
    Fonarow GC
    Rev Cardiovasc Med; 2000; 1(1):25-33, 54. PubMed ID: 12457149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical therapy versus implantable cardioverter -defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: a meta-analysis of > 35,000 patients.
    Peck KY; Lim YZ; Hopper I; Krum H
    Int J Cardiol; 2014 May; 173(2):197-203. PubMed ID: 24636548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons from the management of chronic heart failure.
    McDonagh TA
    Heart; 2005 May; 91 Suppl 2(Suppl 2):ii24-7; discussion ii31, ii43-8. PubMed ID: 15831605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing congestive heart failure.
    Cohn JN
    Am Fam Physician; 1998 Apr; 57(8):1901-4. PubMed ID: 9575327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF.
    Heywood JT; Fonarow GC; Yancy CW; Albert NM; Curtis AB; Gheorghiade M; Inge PJ; McBride ML; Mehra MR; O'Connor CM; Reynolds D; Walsh MN
    Circ Heart Fail; 2010 Sep; 3(5):596-605. PubMed ID: 20634483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Team-Based Care for Outpatients with Heart Failure.
    Creaser JW; DePasquale EC; Vandenbogaart E; Rourke D; Chaker T; Fonarow GC
    Heart Fail Clin; 2015 Jul; 11(3):379-405. PubMed ID: 26142637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and risk factors of asymptomatic first-dose hypotension with angiotensin-converting enzyme inhibitors in chronic heart failure due to systolic dysfunction.
    Thanikachalam S; Manchanda SC
    Indian Heart J; 2003; 55(2):167-71. PubMed ID: 12921333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stage B heart failure: rationale for screening.
    Atherton JJ
    Heart Fail Clin; 2012 Apr; 8(2):273-83. PubMed ID: 22405666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.